Preliminary findings suggest that major medical centers may be able to sustain operations indefinitely by opening "longevity clinics" designed to treat the underlying condition of currently being alive. While longitudinal outcomes remain uncertain, administrators report highly favorable revenue responses to the new therapeutic model.
A retrospective analysis of the burgeoning longevity sector, published this week in an academic financial journal, observed a strong correlation between the deployment of hospital-grade hyperbaric oxygen chambers and immediate, double-digit spikes in out-of-pocket patient expenditures. The protocol typically involves identifying a cohort of asymptomatic, high-net-worth individuals and administering a rigorous regimen of VO2 max testing, continuous glucose monitoring, and unproven red-light therapies until their fear of cellular degradation temporarily subsides.
Researchers noted that unlike traditional oncology or cardiology wards—where billing is tragically limited by a patient either recovering or succumbing to their illness—the longevity model offers a sustained, perhaps lifelong, therapeutic window. By defining natural human aging as an acute medical crisis, health systems have successfully expanded their addressable market to include anyone who currently possesses both a pulse and a premium-tier credit card.
While the clinical efficacy of weekly NAD+ infusions remains inconclusive, our findings regarding their ability to generate non-insurance-dependent cash flow are statistically undeniable.
The FDA has yet to officially approve indefinite survival as a medical necessity, prompting several health systems to classify their $15,000-a-month executive wellness packages as experimental interventions. However, safety screenings indicate the primary adverse event associated with the clinics is mild to severe depletion of liquid assets, though experts caution this symptom appears highly localized to the patient and does not negatively impact the administering facility.
At present, independent regulatory boards are advising caution, noting that until double-blind studies can definitively prove whether aging can be cured, hospitals should continue to administer costly biological age tests just in case.